Menu
Search icon
  1. Home Page
    2. ›
  2. Counties
    3. ›
  3. Broome
    4. ›
  4. 13827
    5. ›
  5. CELL PRESERVATION SERVICES, INC.

CELL PRESERVATION SERVICES, INC.

Company claim

Is this your business?

Get access!

Company Details

Name: CELL PRESERVATION SERVICES, INC.
Jurisdiction: New York
Legal type: DOMESTIC BUSINESS CORPORATION
Status: Active
Date of registration: 17 Dec 2003 (21 years ago)
Entity Number: 2989930
ZIP code: 13827
County: Broome
Place of Formation: New York
Address: 2 COURT STREET, OWEGO, NY, United States, 13827

Shares Details

Shares issued 100000

Share Par Value 0.001

Type PAR VALUE

DOS Process Agent

Name Role Address
JOHN M BAUST PL D DOS Process Agent 2 COURT STREET, OWEGO, NY, United States, 13827

Chief Executive Officer

Name Role Address
JOHN M BAUST PL D Chief Executive Officer 2 COURT STREET, OWEGO, NY, United States, 13827

U.S. Small Business Administration Profile

The U.S. Small Business Administration (SBA) helps Americans start, grow, and build resilient businesses.

Note: SBA was created in 1953 as an independent agency of the federal government to aid, counsel, assist and protect the interests of small business concerns; preserve free competitive enterprise; and maintain and strengthen the overall economy of our nation. SBA reviews Congressional and testifies on behalf of small businesses. It assesses the impact of regulatory burden on small businesses.

Website:
www.CPSIbiotech.com
Phone Number:
607-687-8701
E-mail Address:
jmbaust@cellpreservation.com
Fax Number:
607-348-1516
Contact Person:
JOHN BAUST
User ID:
P0653823
Trade Name:
CELL PRESERVATION SERVICES INC

Unique Entity ID

A UEI is a government-provided number, like a tax ID number, that’s used to identify businesses eligible for federal grants, awards and contracts.

Note: In April 2022, the federal government replaced its old identifier of choice, the Data Universal Numbering System (DUNS) number, with a government-issued UEI. Now all the federal government’s Integrated Award Environment systems use UEI numbers instead of DUNS numbers. So any entity doing business with the federal government must register for a UEI.

Unique Entity ID:
M2G2AJQ88SL5
CAGE Code:
41SK5
UEI Expiration Date:
2025-12-01

Business Information

Doing Business As:
CELL PRESERVATION SERVICES INC
URL:
www.CPSIbiotech.com
Activation Date:
2024-12-02
Initial Registration Date:
2005-07-07

Commercial and government entity program

The The Commercial And Government Entity Code (CAGE) is assigned by the Department of Defense's Defense Logistics Agency (DLA) and represents your company's physical address for GSA's mailings, payments, and administrative records.

Note: A CAGE Code enables a company to contract with the U.S. government, allowing bid on government contracts and to receive government payments. Also for business this means that it's a Verified business entity and Has a validated physical address.

CAGE number:
41SK5
Status:
Active
Type:
U.S./Canada Manufacturer
CAGE Update Date:
2024-03-09
CAGE Expiration:
2028-12-06
SAM Expiration:
2024-12-03

Contact Information

POC:
JOHN M. BAUST
Phone:
+1 607-687-8701
Fax:
+1 607-348-1516

Form 5500 Series

Employer Identification Number (EIN):
200641296
Plan Year:
2023
Number Of Participants:
7
Sponsors Telephone Number:
6076878701
File:
View File
Plan Year:
2022
Number Of Participants:
9
Sponsors Telephone Number:
6076878701
File:
View File
Plan Year:
2021
Number Of Participants:
11
Sponsors Telephone Number:
6076878701
File:
View File
Plan Year:
2020
Number Of Participants:
12
Sponsors Telephone Number:
6076878701
File:
View File
Plan Year:
2019
Number Of Participants:
8
Sponsors Telephone Number:
6076878701
File:
View File

History

Start date End date Type Value
2003-12-17 2006-01-18 Address SUITE 144 - SCIENCE III, SUNY PARK, BINGHAMTON, NY, 13902, USA (Type of address: Service of Process)

Filings

Filing Number Date Filed Type Effective Date
140109002056 2014-01-09 BIENNIAL STATEMENT 2013-12-01
120124002164 2012-01-24 BIENNIAL STATEMENT 2011-12-01
091208002272 2009-12-08 BIENNIAL STATEMENT 2009-12-01
071224003272 2007-12-24 BIENNIAL STATEMENT 2007-12-01
060118002289 2006-01-18 BIENNIAL STATEMENT 2005-12-01

USAspending Awards / Contracts

Procurement Instrument Identifier:
W81XWH15C0102
Link:
View Award on USAspending website
Award Or Idv Flag:
AWARD
Award Type:
DEFINITIVE CONTRACT
Action Obligation:
149973.45
Base And Exercised Options Value:
149973.45
Base And All Options Value:
149973.45
Awarding Agency Name:
Department of Defense
Performance Start Date:
2015-09-28
Description:
IGF::OT::IGF. SBIR PHASE I DHP 15.1 H151-014-0078. "OPTIMAL REWARMING SOLUTIONS FOR CRYOPRESERVED TISSUE SYSTEMS."
Naics Code:
541711: RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY
Product Or Service Code:
AN83: R&D- MEDICAL: AIDS RESEARCH (ADVANCED DEVELOPMENT)
Procurement Instrument Identifier:
AG82HWP090058
Link:
View Award on USAspending website
Award Or Idv Flag:
AWARD
Award Type:
PO
Action Obligation:
19998.00
Base And Exercised Options Value:
19998.00
Base And All Options Value:
19998.00
Awarding Agency Name:
Department of Agriculture
Performance Start Date:
2009-09-08
Description:
CONSULTING SERVICES TO ASSIST IN THE DEVELOPMENT OF A PROCESS FOR THE AUTOMATION OF CRYOPRESERVATION OF SCREWWORM EMBRYOS.
Naics Code:
541690: OTHER SCIENTIFIC AND TECHNICAL CONSULTING SERVICES
Product Or Service Code:
R406: POLICY REVIEW/DEVELOPMENT SERVICES

USAspending Awards / Financial Assistance

Date:
2024-04-18
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
A NOVEL MULTICOMPONENT DMSO FREE CRYOCOCKTAIL AND RECOVERY REAGENT FOR THE IMPROVED CRYOPRESERVATION OF NK CELLS - ABSTRACT THE ULTIMATE GOAL OF CRYOPRESERVATION (CP) IS TO DEVELOP A BIOBANKING PROCESS THAT RESULTS IN A POST-THAW LEVEL OF CELL VIABILITY AND FUNCTION SIMILAR TO A SISTER POPULATION THAT HAS NOT UNDERGONE CP. MOST METHODS USED FOR THE CLINICAL LEVEL CP OF HUMAN NATURAL KILLER (NK) CELLS AND OTHER CELL THERAPY CELLS RESULT IN POOR RECOVERY DUE TO POST-THAW NECROSIS AND APOPTOSIS YIELDING AN INFERIOR CELL PRODUCT WHICH IS INFUSED INTO PATIENTS. OUR RESEARCH TEAM HAS SHOWN THROUGH DOZENS OF PUBLICATIONS THAT HUMAN STEM AND SOMATIC CELLS UNDERGO DELAYED ONSET CELL DEATH TRIGGERED PRIMARILY BY APOPTOSIS THAT OCCURS OVER A SEVERAL DAY PERIOD POST THAW. THESE PUBLICATIONS SUPPORT THE FOLLOWING QUESTIONS CRITICAL TO THE CLINICAL USE OF CP SOLUTIONS: (1) HOW MUCH OF THE OBSERVED IN VIVO CELL LOSS ASSOCIATED WITH POST-THAW INFUSION OF CRYOPRESERVED CELLS IS A RESULT OF THE MANIFESTATION OF DELAYED ONSET CELL DEATH THAT IS ATTRIBUTABLE TO THE CP SOLUTION AND POST-THAW PROTOCOL USED IN THE CLINIC? (2) WHAT TRIGGERS THE APOPTOTIC CASCADE THAT RESULTS IN DELAYED ONSET CELL DEATH? ONE HYPOTHESIS TO BE TESTED IN THIS PHASE I PROPOSAL IS THAT THIS DELAYED ONSET CELL DEATH MAY BE A RESULT OF CP-TRIGGERED PREMATURE CELL AGING AND SENESCENCE – A HYPOTHESIS THAT IS SUPPORTED BY OUR GROUP’S PUBLICATIONS SHOWING THAT RESVERATROL, AN ACTIVATOR OF THE SIRTUIN (LONGEVITY) GENES, CAN IMPROVE POST HYPOTHERMIC PRESERVATION OUTCOME BY UP TO 10 FOLD IN HUMAN HEPATOCYTES AND MESENCHYMAL STEM CELLS. BUT THIS AGENT COULD ALSO BE ACTING THROUGH OTHER MOLECULAR MEANS AS WELL. GIVEN, HOWEVER, A JULY, 2023, PUBLICATION REPORTING THAT SELECT CHEMICAL COCKTAILS HAVE BEEN FORMULATED THAT CAN REVERSE THE CELL AGING PROCESS THIS HYPOTHESIS CAN NOW BE TESTED USING CP SOLUTIONS AND POST-THAW REVIVAL FORMULATIONS THAT CONTAIN THESE NON-PROPRIETARY AGE-REVERSING CHEMICALS. SINCE, OVER HALF OR MORE OF ALL CELL THERAPY PRODUCTS IN CLINICAL TRIALS TODAY, INCLUDING NK CELLS, ARE CRYOPRESERVED IN 10% DMSO WHICH IS HIGHLY TOXIC, MANY STUDIES HAVE INVESTIGATED WAYS TO IMPROVE CP AS WELL AS TO USE ALTERNATIVE CRYOPROTECTIVE AGENTS (CPAS) SUCH AS SUGAR ALCOHOLS TO AVOID THE KNOWN TOXICITY OF DMSO. INDEED, A SYMPOSIUM AT CRYO2023 WAS SOLELY DEDICATED TO DISCUSSING ALTERNATIVES TO DMSO AS CPAS MAKING THIS FOCUS A HIGH PRIORITY IN THE CP SCIENCES. YET, TO DATE NO NEW CP PROCESS THAT ELIMINATES DMSO HAS BEEN DEVELOPED COMMERCIALLY. TO ACHIEVE THIS MILESTONE, FIRST, DMSO MUST BE REPLACED WITH CPAS THAT CAN PREVENT THE FORMATION AND RE-CRYSTALLIZATION OF LETHAL ICE DURING THE CP PROCESS. SECOND, A POST-THAW RECOVERY CONDITIONING DILUTION/INFUSION REAGENT MUST BE DEVELOPED THAT CAN PREVENT POST-THAW DELAYED ONSET CELL DEATH AND IMPROVE NK CELL VIABILITY AND FUNCTION IMMEDIATELY FOLLOWING THAWING. SPECIFIC AIMS OF THIS PROJECT ARE THE FOLLOWING: SA1) DEVELOP CHILLOUT - A NON-TOXIC CPA CRYOCOCKTAIL TO REPLACE DMSO; SA2) FORMULATE REVITALICE – A FIRST IN CLASS CP DILUTION REAGENT DESIGNED TO AMELIORATE POST-THAW APOPTOSIS/NECROSIS INCREASING NK SURVIVAL AND INFUSION EFFICACY AND SA3) EVALUATE NK CELL CYTOTOXIC FUNCTION FOLLOWING CP. HYPOTHESES TO BE TESTED IN THIS PHASE I PROJECT ARE THE FOLLOWING: (1) THE APOPTOSIS-DEPENDENT DELAYED ONSET CELL DEATH IS INITIALLY TRIGGERED BY CP-INDUCED PREMATURE CELL AGING LEADING TO POOR CP OUTCOME; (2) NK CP CELL SURVIVAL AND FUNCTION CAN BE IMPROVED THROUGH THE ADDITION OF CELL STRESS MODULATORS AND AGE-REVERSING CHEMICAL COCKTAILS; AND (3) ELIMINATION OF DMSO WILL FURTHER REDUCE NK STRESS ASSOCIATED WITH CP. HYPOTHESES TO BE TESTED IN THE PHASE II PROJECT ARE THE FOLLOWING: (1) A DMSO FREE CP SOLUTION CAN BE DEVELOPED WITH CELL STRESS AND AGE-REVERSING MODULATORS THAT IS FDA AND CLINICALLY ACCEPTABLE FOR THERAPEUTIC APPLICATION AND RESULTS IN BETTER POST CP OUTCOME THAN TRADITIONAL SOLUTIONS CONTAINING 10% DMSO: (2) DELAYED ONSET CELL DEATH OCCURS IN VIVO IN ANIMAL MODELS IF NK CELLS ARE STORED IN DMSO-CONTAINING CP SOLUTIONS BUT DOES NOT OCCUR IF THE PROPOSED CHILLOUT AND REVITALICE CONTAINING CELL STRESS AND AGE-REVERSING MODULATORS ARE USED AS THE CP FORMULATIONS AND POST-THAW REVIVAL SOLUTIONS. THESE EFFORTS WILL RESULT IN IMPROVED NK AND OTHER CELL THERAPY CELL CP AND THEREBY IMPROVE CLINICAL OUTCOME FOR PATIENTS RECEIVING THESE CELLS.
Obligated Amount:
306000.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2022-09-22
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
FROSTBITE-DMR - A NEW DRUG-FREE APPROACH FOR TREATING TYPE 2 DIABETES - TYPE 2 DIABETES MELLITUS (T2D) IS INCREASING IN INCIDENCE THROUGHOUT THE WORLD WITH NEARLY 552 MILLION PEOPLE WHO MAY BE AFFLICTED WITH THIS DISEASE BY 2030. THERE ARE NOW OVER 50 DIFFERENT DRUGS THAT CAN BE USED TO TREAT T2D BUT ABOUT HALF OF PATIENTS DO NOT RESPOND WELL TO THESE AGENTS AND THEIR HYPERGLYCEMIC CONDITION REMAINS A LIFE-THREATENING PROBLEM. INDEED, THE FIRST LINE DRUGS SUCH AS METFORMIN, GLP-1 RECEPTOR AGONISTS (E.G. SEMAGLUTIDE), DPP-4 INHIBITORS, SGLT2 INHIBITORS AND OTHERS HAVE DOCUMENTED SIDE EFFECTS THAT INCLUDE HYPOGLYCEMIA, GASTROINTESTINAL SIDE EFFECTS, PANCREATITIS, PANCREATIC CANCER, THYROID CANCER, GALLBLADDER ISSUES, CARDIOVASCULAR CHANGES, ACUTE KIDNEY INJURY, DIABETIC RETINOPATHY, ALLERGIC REACTIONS, INCREASE IN BILIARY DISEASE, CHANGE IN TASTE AND HEADACHES. AS AN ALTERNATIVE TO THESE DRUGS, THE FIRST IN HUMAN REPORT WAS PUBLISHED IN 2016 SHOWING THAT DUODENAL MUCOSAL RESURFACING (DMR) OF T2D PATIENTS COULD IMPROVE THEIR HYPERGLYCEMIC CONDITIONS AS WELL AS SEVERAL HEPATIC INDICES WITHOUT HAVING TO USE THESE FRONT LINE DRUGS. THIS STUDY WAS INITIATED, IN PART, BECAUSE OF THE WELL DOCUMENTED AND SURPRISING OBSERVATION THAT BARIATRIC SURGERY ALSO RESULTED IN A SIMILAR BENEFIT TO T2D PATIENTS THAT WAS INDEPENDENT OF CONSEQUENTIAL WEIGHT LOSS. SINCE 2016 SEVERAL CLINICAL STUDIES HAVE BEEN CONDUCTED ON DMR AND ALL SHOWED BENEFIT TO PATIENTS WITH T2D WHO WEREN’T RESPONDING TO TRADITIONAL MEDICAL TREATMENTS OR WHO WERE NON- COMPLIANT WITH MEDICATIONS. WHILE PROMISING, DMR HAS BEEN REPORTED TO HAVE A HIGH RATE OF TECHNICAL FAILURE DUE TO CATHETER MALFUNCTIONING SUGGESTING THAT IMPROVEMENTS IN THE TECHNICAL-FUNCTIONAL ASPECTS OF CURRENT DEVICES NEED TO BE ADDRESSED. FURTHERMORE, ONE SUCH DMR DEVICE THAT HAS SHOWN BENEFIT IN SEVERAL CLINICAL TRIALS USES HYDROTHERMIC ABLATION (HOT WATER AT 80 TO 90°C) TO ACHIEVE DMR. LIKE RADIOFREQUENCY ABLATION, HIFU, MICROWAVE AND OTHER HEAT ABLATION TECHNOLOGIES USED TO TARGET AND ABLATE TUMORS AND TREAT CARDIAC ARRHYTHMIAS, THE PASSIVE SPREAD OF HEAT CAN’T BE EASILY CONTROLLED AND HAS SHOWN TO RESULT IN COLLATERAL TISSUE DAMAGE SUCH AS MUSCULAR SEGMENTAL NECROSIS AND SEROSA BLEEDING WITH POSTOPERATIVE ADVERSE EVENTS FROM DMR HYDROTHERMIC ABLATION REPORTED TO BE AN ISSUE WITH 64% OF THE CASES. CPSI BIOTECH INTENDS TO CAPITALIZE ON THIS EMERGING DMR MARKET THAT IS CURRENTLY IN ITS INFANCY AND DEVELOP AN IMPROVED DMR THERMAL ABLATION PROBE THAT USES FREEZING (CRYOABLATION) RATHER THAN HEAT FOR DUODENAL RESURFACING. THE ADVANTAGES OF THE PROPOSED FROSTBITE- DMR CRYOBALLOON INCLUDE (A) FREEZING IS SELF-LIMITING IN CONTRAST TO HEAT AND PRESENTS LESS OPPORTUNITY FOR COLLATERAL DAMAGE TO ADJACENT DEEPER DUODENAL TISSUE; (B) CRYOABLATION HAS BEEN SHOWN TO BE MORE EFFECTIVE, SAFER AND HAVE FEWER COMPLICATIONS THAN HEAT BASED ABLATION IN NUMEROUS TISSUES INCLUDING CARDIAC, ESOPHAGEAL, RENAL, PROSTATE AND PANCREATIC AMONG OTHERS; (C) CPSI’S PSN CRYOABLATION SYSTEMS CAN GENERATE AND DELIVER ABLATIVE TEMPERATURES FASTER AND COLDER THAN ANY OTHER KNOWN CRYOABLATION SYSTEMS CURRENTLY ON THE MARKET THUS DECREASING PROCEDURAL TIME AND, AS SUCH, WILL OFFER IMPROVED VERSATILITY AND SAFETY COMPARED TO CURRENT TECHNOLOGIES. THE SPECIFIC AIMS OF THIS PROJECT ARE THE FOLLOWING: (SA1) DETERMINE THE THERMAL ABLATIVE DOSE OF DUODENUM CELLS SUBJECTED TO CRYOABLATION; (SA2) DEVELOP FROSTBITE-DMR™, A FLEXIBLE ENDOSCOPE COMPATIBLE CRYOBALLOON, AND (SA3) TEST THE EFFICACY OF FROSTBITE IN EX VIVO AND IN VIVO MODELS. THE OVERALL INTENT OF THE PROJECT IS TO CAPITALIZE ON THE DOCUMENTED SUCCESS OF DMR PUBLISHED IN THE LAST FEW YEARS AS WELL AS CPSI’S EXPERTISE IN DEVELOPING IMPROVED CRYOABLATION CATHETERS SO THAT AN IMPROVED DMR ABLATION DEVICE CAN BE DEVELOPED THAT IS SAFER, MORE EFFICIENT, AND CAN BE BETTER OPERATOR CONTROLLED LEADING TO MORE SUCCESSFUL DMR FOR T2D PATIENTS WHO DO NOT RESPOND WELL TO CURRENT T2D DRUG TREATMENTS.
Obligated Amount:
310376.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2021-01-23
Link:
View on USAspending
Awarding Agency Name:
Small Business Administration
Transaction Description:
TO AID SMALL BUSINESSES IN MAINTAINING WORK FORCE DURING COVID-19 PANDEMIC.
Obligated Amount:
0.00
Face Value Of Loan:
110947.00
Total Face Value Of Loan:
110947.00
Date:
2020-06-19
Link:
View on USAspending
Awarding Agency Name:
Small Business Administration
Transaction Description:
TO PROVIDE LOANS TO RESTORE AS NEARLY AS POSSIBLE THE VICTIMS OF ECONOMIC INJURY TYPE DISASTERS TO PRE-DISASTER CONDITIONS
Obligated Amount:
0.00
Face Value Of Loan:
150000.00
Total Face Value Of Loan:
643400.00
Date:
2020-04-15
Link:
View on USAspending
Awarding Agency Name:
Small Business Administration
Transaction Description:
TO AID SMALL BUSINESSES IN MAINTAINING WORK FORCE DURING COVID-19 PANDEMIC.
Obligated Amount:
0.00
Face Value Of Loan:
110900.00
Total Face Value Of Loan:
110900.00

Trademarks Section

Serial Number:
85285106
Mark:
ICEOLATE
Status:
ABANDONED - NO STATEMENT OF USE FILED
Mark Type:
TRADEMARK
Application Filing Date:
2011-04-04
Mark Drawing Type:
Standard character mark
Mark Literal Elements:
ICEOLATE
USPTO Link:
View Trademark Status and Document Retrieval (TSDR)

Goods And Services

For:
Cryosurgical probes; Medical and surgical catheters
International Classes:
010 - Primary Class
Class Status:
Active

Paycheck Protection Program

Date Approved:
2021-01-23
Loan Status:
Paid in Full
SBA Guaranty Percentage:
100
Initial Approval Amount:
110947
Current Approval Amount:
110947
Race:
Unanswered
Ethnicity:
Not Hispanic or Latino
Gender:
Male Owned
Veteran:
Non-Veteran
Forgiveness Amount:
112138.54
Date Approved:
2020-04-15
Loan Status:
Paid in Full
SBA Guaranty Percentage:
100
Initial Approval Amount:
110900
Current Approval Amount:
110900
Race:
Unanswered
Ethnicity:
Not Hispanic or Latino
Gender:
Male Owned
Veteran:
Non-Veteran
Forgiveness Amount:
111711.24

Reviews Leave a review

This company hasn't received any reviews.

Related by officers

No related officers

Related by address

2 COURT STREET, OWEGO, NY, United States, 13827

CPSI HOLDINGS LLC CSO 2 PROPERTIES LLC

Date of last update: 29 Mar 2025

Sources: New York Secretary of State

Privacy policy Policy
About us About us
Contacts Contact us

© 2025 bizyork.com, Part of Big Data Integrated